Fluor (FLR) Q3 2017 Results - Earnings Call Transcript

By Sean Alyeshmerni, DO We find Vital Therapeutics (NASDAQ:VTL) to be a good buy at its current market price of about $6.00/share, with a target price of $7.87 for the 12-month time frame, following solid 2Q17...

Continue reading at Seeking Alpha →
Recommended posts powered by Google